Financial overview

BerGenBio financial report data and keyfigures. History for income statement, balance sheet and cash flow.

Pre
Pre
Pre
Pre
Pro
Pro
Created with Highcharts 9.0.1

Description

BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases.  The company’s clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.

Biotechnology